{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:49:33Z","timestamp":1778575773894,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40266-026-01281-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:54:55Z","timestamp":1771527295000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-0277","authenticated-orcid":false,"given":"Javier","family":"Loricera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Molina-Collada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"S\u00e1nchez-Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Silva-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eztizen","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1281_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","volume":"347","author":"C Salvarani","year":"2002","unstructured":"Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261\u201371.","journal-title":"N Engl J Med"},{"key":"1281_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50\u20137.","journal-title":"N Engl J Med"},{"key":"1281_CR3","doi-asserted-by":"publisher","first-page":"1296393","DOI":"10.3389\/fmed.2023.1296393","volume":"10","author":"HK Skaug","year":"2023","unstructured":"Skaug HK, Fevang BT, Assmus J, et al. Giant cell arteritis: incidence and phenotypic in Western Norway 2013\u20132020. Front Med (Lausanne). 2023;10:1296393.","journal-title":"Front Med (Lausanne)."},{"key":"1281_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","volume":"16","author":"M Samson","year":"2017","unstructured":"Samson M, Corbera-Bellalta M, Audia S, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017;16:833\u201344.","journal-title":"Autoimmun Rev"},{"key":"1281_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"1281_CR6","first-page":"1051","volume":"75","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2016;75:1051\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1281_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3899\/jrheum.151252","volume":"43","author":"A R\u00e9gent","year":"2016","unstructured":"R\u00e9gent A, Redeker S, Deroux A, et al. Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol. 2016;43:1547\u201352.","journal-title":"J Rheumatol"},{"key":"1281_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","volume":"23","author":"SH Unizony","year":"2021","unstructured":"Unizony SH, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23:8.","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 129","key":"1281_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.55563\/clinexprheumatol\/mjm8fr","volume":"39","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a D, Mart\u00ednez-Rodr\u00edguez I, Atienza-Mateo B, et al. Evidence for uncoupling of clinical and 18-FDG activity of PET\/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clin Exp Rheumatol. 2021;39(Suppl 129):69\u201375.","journal-title":"Clin Exp Rheumatol"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73:1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"1281_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"1281_CR12","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1093\/rheumatology\/keac097","volume":"61","author":"A Herrero-Morant","year":"2022","unstructured":"Herrero-Morant A, Mart\u00edn-Varillas JL, Casta\u00f1eda S, et al. Biologic therapy in refractory neuro Beh\u00e7et\u2019s disease: a multicentre study of 41 patients and literature review. Rheumatology (Oxford). 2022;61:4427\u201336.","journal-title":"Rheumatology (Oxford)"},{"key":"1281_CR13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanju\u00e1n","year":"2014","unstructured":"Ortiz-Sanju\u00e1n F, Blanco R, Calvo-R\u00edo V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"1281_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/ard-2024-225854","volume":"83","author":"S Bindoli","year":"2024","unstructured":"Bindoli S, De Matteis A, Mitrovic S, et al. Efficacy and safety of therapies for Still\u2019s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still\u2019s disease. Ann Rheum Dis. 2024;83:1731\u201347.","journal-title":"Ann Rheum Dis"},{"key":"1281_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9:2816.","journal-title":"J Clin Med"},{"key":"1281_CR16","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/s41433-025-03845-8","volume":"39","author":"AG Abumohssin","year":"2025","unstructured":"Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A. Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves\u2019 orbitopathy: a systematic review and meta-analysis. Eye Lond. 2025;39:1901\u201332.","journal-title":"Eye Lond"},{"key":"1281_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.semarthrit.2020.03.023","volume":"50","author":"C Dom\u00ednguez-Casas","year":"2020","unstructured":"Dom\u00ednguez-Casas C, S\u00e1nchez-Bilbao L, Calvo-R\u00edo V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020;50:608\u201315.","journal-title":"Semin Arthritis Rheum"},{"key":"1281_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211020917","volume":"13","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a D, Bernabeu P, Vela P, et al. Tocilizumab in refractory Caucasian Takayasu\u2019s arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211020917.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1281_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1084558","volume":"14","author":"L Kang","year":"2023","unstructured":"Kang L, Liu Y, Luo Z, Zhou Y, Chen B, Yin G, et al. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis. Front Immunol. 2023;14:1084558.","journal-title":"Front Immunol"},{"key":"1281_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004514","volume":"10","author":"JS Smolen","year":"2024","unstructured":"Smolen JS, Trefler J, Racewicz A, et al. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomized, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024;10:e004514.","journal-title":"RMD Open"},{"key":"1281_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40261-025-01453-8","volume":"45","author":"G Burmester","year":"2025","unstructured":"Burmester G, Trifler J, Racewicz A, et al. Efficacy and safety of biosimilar CT-P47 versus reference tocilizumab: 1-year results of a randomized, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis. Clin Drug Investig. 2025;45:551\u201363.","journal-title":"Clin Drug Investig"},{"key":"1281_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122\u20138.","journal-title":"Arthritis Rheum"},{"key":"1281_CR23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1136\/ard-2022-223480","volume":"81","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647\u201353.","journal-title":"Ann Rheum Dis"},{"key":"1281_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.","journal-title":"PLoS Med"},{"key":"1281_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024;83:48\u201357.","journal-title":"Ann Rheum Dis"},{"key":"1281_CR26","unstructured":"Narv\u00e1ez J, Dom\u00ednguez-\u00c1lvaro M, Hern\u00e1ndez-Rodr\u00edguez I, ARTESER Project Collaborative Group et al. Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry. Rheumatology (Oxford). 2025 (In press)."},{"key":"1281_CR27","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1093\/rheumatology\/keae666","volume":"64","author":"R Blanco","year":"2025","unstructured":"Blanco R, Aldasoro V, Maiz O, et al. Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Rheumatology (Oxford). 2025;64:2928\u201336.","journal-title":"Rheumatology (Oxford)"},{"key":"1281_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221113747","volume":"14","author":"J Loricera","year":"2022","unstructured":"Loricera J, Casta\u00f1eda S, Moriano C, et al. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients. Ther Adv Musculoskelet Dis. 2022;14:1759720X221113747.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1281_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2024.06.013","volume":"129","author":"A Mart\u00edn-Guti\u00e9rrez","year":"2024","unstructured":"Mart\u00edn-Guti\u00e9rrez A, Loricera J, Narv\u00e1ez J, et al. Effectiveness of tocilizumab in aortitis and aneurysms associated with giant cell arteritis. Eur J Intern Med. 2024;129:78\u201386.","journal-title":"Eur J Intern Med"},{"key":"1281_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152640","volume":"71","author":"A Mart\u00edn-Guti\u00e9rrez","year":"2025","unstructured":"Mart\u00edn-Guti\u00e9rrez A, Loricera J, Aldasoro V, et al. Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. Semin Arthritis Rheum. 2025;71:152640. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152640.","journal-title":"Semin Arthritis Rheum"},{"key":"1281_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152153","volume":"58","author":"N Barroso-Garc\u00eda","year":"2023","unstructured":"Barroso-Garc\u00eda N, Atienza-Mateo B, Ferraz-Amaro I, et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 132","key":"1281_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","volume":"39","author":"B Atienza-Mateo","year":"2021","unstructured":"Atienza-Mateo B, Beltr\u00e1n E, Hern\u00e1ndez-Garfella M, et al. Tocilizumab in Beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021;39(Suppl 132):37\u201342.","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 102","key":"1281_CR33","first-page":"S34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S34\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"1281_CR34","doi-asserted-by":"crossref","unstructured":"Sota J, Breda L, Paroli MP, Hashad S, de la Torre A, Guerriero S, et al. Tocilizumab effectiveness in paediatric non-infectious uve\u00edtis: data from the International AIDA Network Registries on ocular inflammatory disorders. Br J Ophthalmol. 2025 (In press).","DOI":"10.1136\/bjo-2025-327410"},{"key":"1281_CR35","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1185\/03007995.2015.1098601","volume":"31","author":"P Declerck","year":"2015","unstructured":"Declerck P, Mellstedt H, Danese S. Biosimilars\u2014terms of use. Curr Med Res Opin. 2015;31:2325\u201330.","journal-title":"Curr Med Res Opin"},{"key":"1281_CR36","first-page":"469","volume":"6","author":"EA Blackstone","year":"2013","unstructured":"Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6:469\u201378.","journal-title":"Am Health Drug Benefits"},{"key":"1281_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4:e00208.","journal-title":"Pharmacol Res Perspect"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01281-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:01:48Z","timestamp":1773802908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01281-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: J. Loricera had consultation fees\/participation in company-sponsored speaker\u2019s bureau from Roche, AbbVie, Gal\u00e1pagos, Alpha Sigma, Novartis, UCB Pharma, MSD, Celgene, Astra Zeneca, and Gr\u00fcnenthal and received support for attending meetings and\/or travel from Janssen, AbbVie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, and Gal\u00e1pagos. J.C. Nieto had consultation fees\/participation in company-sponsored speaker\u2019s bureau from Abbvie, Gal\u00e1pagos, Alpha Sigma, Janssen, Sandoz, Nordic, Pfizer, Lilly, UCB, MSD, GSK and Astra Zeneca. Mar\u00eda Teresa Silva-D\u00edaz had consultation fees\/participation in company-sponsored speaker\u2019s bureau from Grunenthal, FAES Pharma, Abbvie and Pfizer and received support for attending meetings and\/or travel from Rubi\u00f3 and Lilly. P. Moya had consultation fees\/participation in company-sponsored speaker\u2019s bureau from Abbvie and GSK and received support for attending meetings and\/or travel from Abbvie and Lilly. I. Ferraz-Amaro has received grants\/research supports from Abbvie, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speaker\u2019s bureau associated with Abbvie, Pfizer, Roche, Sanofi, Celgene, and MSD and received support for attending meetings and\/or travel from Abbvie, MSD, Janssen, Pfizer, Roche, Sanofi, and Celgene. R. Blanco received grants\/research support from AbbVie, MSD, and Roche, had consultation fees\/participation in a company-sponsored speaker\u2019s bureau from AbbVie, Pfizer, Roche, GSK, Lilly, UCB, Bristol-Myers, Novartis, Janssen, UCB and MSD, and received support for attending meetings and\/or travel from AbbVie, Pfizer, Roche, GSK, Lilly, UCB, Bristol-Myers, Novartis, Janssen, UCB, and MSD. The following authors did not declare financial disclosures: J. Molina-Collada, M. S\u00e1nchez Lucas, and Eztizen Labrador.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Javier Loricera and Ricardo Blanco conceptualized and designed the study. Javier Loricera and Ricardo Blanco were the research coordinators for the study. Javier Loricera and Ricardo Blanco were the project managers for the study. Iv\u00e1n Ferraz-Amaro supervised the study. Javier Loricera, Juan Molina-Collada, Juan Carlos Nieto, Marina S\u00e1nchez-Lucas, Mar\u00eda Teresa Silva-D\u00edaz, Patricia Moya, and Eztizen Labrador collected data. Javier Loricera, Iv\u00e1n Ferraz-Amaro, and Ricardo Blanco curated the data. Javier Loricera, Iv\u00e1n Ferraz-Amaro, and Ricardo Blanco analyzed the data. Javier Loricera, Iv\u00e1n Ferraz-Amaro, and Ricardo Blanco interpreted the data. Javier Loricera wrote the original manuscript. Javier Loricera, Juan Molina-Collada, Juan Carlos Nieto, Marina S\u00e1nchez-Lucas, Mar\u00eda Teresa Silva-D\u00edaz, Patricia Moya, Eztizen Labrador, Iv\u00e1n Ferraz-Amaro, and Ricardo Blanco reviewed and edited the original manuscript. Javier Loricera and Ricardo Blanco had direct access to the data and verified the underlying raw data reported in the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. In addition, all authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors confirm that all data supporting the findings of this study are fully available without restriction. All relevant data are contained within the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Stata version 17\/SE (StataCorp, College Station, TX, USA).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was approved by the Cantabria Clinical Research Ethics Committee (internal code: 2025.058) and conducted in compliance with the Declaration of Helsinki and ICH Good Clinical Practice guidelines. All data extracted from the medical records were stored deidentified prior to the analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As per the Clinical Research Ethics Committee, this retrospective research did not require informed consent.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI and AI-assisted technologies in the writing process"}}]}}